About: New loss of smell and taste: Uncommon symptoms in COVID-19 patients on Nord Franche-Comte cluster, France

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: New loss of smell and taste: Uncommon symptoms in COVID-19 patients on Nord Franche-Comte cluster, France Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	New loss of smell and taste: Uncommon symptoms in COVID-19 patients on Nord Franche-Comte cluster, France
Creator	Gendrin, Vincent Kadiane-Oussou, Juliette Klopfenstein, Timothée Lepiller, Quentin Royer, Pierre-Yves Toko, Lynda Zayet, Souheil Zahra, Hajer Zahra, N'dri, Hajer
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: New loss of smell or taste was not included as common symptoms of COVID-19 until March 2020 when the pandemic started in Western countries. We want to describe the prevalence and features of anosmia and dysgeusia in COVID-19 patients. METHODS: We retrospectively investigated the clinical features of confirmed cases of COVID-19 in Nord Franche-Comté Hospital, Trevenans, France, between March, 1st and March, 14th 2020. We used SARS-CoV-2 real time RT-PCR in respiratory samples to confirm the cases. RESULTS: Of 70 patient enrolled, the mean age was 57.0 years and 29 patients (41%) were men. Median Charlson comorbidity index was 1.70(±2.5). Twenty-seven (39%) patients had pneumonia. Fatigue (93% [65]), cough (80% [55]) and fever (77% [54]) were the three main symptoms. Neurologic symptoms were present in more than half of the patients: anosmia (53% [37]) and dysgeusia (48% [34]). The mean duration of anosmia was 7.4 (±5, [1–21]) days, 51% (36/70) recovered before 28 days of evolution. Only one patient with anosmia had not recovered at the end of the follow-up. Patients with anosmia had less often a pneumonia (10/37 vs 17/33, p = 0.036), were less often hospitalized (13/37 vs 20/33, p = 0.033) and needed less often oxygen therapy (6/37 vs 17/33, p = 0.002) than patients without anosmia. There were no statistically differences for viral load between patients with anosmia and patients without anosmia (5.5 [2.0–8.6] vs 5.3 [2.1–8.5] log copies/ml respectively, p = 0.670). The fatality of COVID-19 in our study was 6% with four deaths. CONCLUSIONS: Anosmia and dysgeusia are present in half of COVID-19 patients. The mean duration of anosmia was 7 days and the outcome seems favorable in less than 28 days.
has issue date	2020-08-07(xsd:dateTime)
bibo:doi	10.1016/j.ijid.2020.08.012
bibo:pmid	32771635
has license	no-cc
sha1sum (hex)	682c4ac2f50dff14002785ae077dd09130ab0965
schema:url	https://doi.org/10.1016/j.ijid.2020.08.012
resource representing a document's title	New loss of smell and taste: Uncommon symptoms in COVID-19 patients on Nord Franche-Comte cluster, France
has PubMed Central identifier	PMC7410813
has PubMed identifier	32771635
schema:publication	Int J Infect Dis
resource representing a document's body	covid:682c4ac2f50dff14002785ae077dd09130ab0965#body_text
is schema:about of	named entity 'prevalence' named entity 'Running' named entity 'taste' named entity 'HOW' covid:arg/682c4ac2f50dff14002785ae077dd09130ab0965 named entity 'prognosis' named entity 'loss of smell' named entity 'France' named entity 'arthralgia' named entity 'rhinitis' named entity 'viral genome' named entity 'arthralgia' named entity 'comorbidities' named entity 'coronary heart disease' named entity 'oxygen therapy' named entity 'sputum' named entity 'dysgeusia' named entity 'anosmia' named entity 'mucosal' named entity 'COVID' named entity 'dry eyes' named entity 'diarrhea' named entity 'anosmia' named entity 'nasal cavity' named entity 'Asia' named entity 'anosmia' named entity 'olfactory' named entity 'dysgeusia' named entity 'Institut Pasteur' named entity 'Fisher's exact test' named entity 'medical files' named entity 'evolution' named entity 'Institut Pasteur' named entity 'asthma' named entity 'inflammation' named entity 'anosmia' named entity 'evolution' named entity 'thromboembolic disease' named entity 'anosmia' named entity 'nasal obstruction' named entity 'COVID' named entity 'χ2 test' named entity 'smell or taste' named entity 'coronary heart disease' named entity 'anosmia' named entity 'anosmia' named entity 'COVID-19' named entity 'dysgeusia' named entity 'nausea' named entity 'cardiac arrhythmia' named entity 'RdRp' named entity 'parenchyma' named entity 'olfactory' named entity 'fever' named entity 'anosmia' named entity 'COVID' named entity 'asthma' named entity 'coronaviruses' named entity 'HCoV-229E' named entity 'China' named entity 'dysgeusia' named entity 'RT-PCR' named entity 'cardiac failure' named entity 'infection' named entity 'lesion' named entity 'dysgeusia' named entity 'hearing loss' named entity 'nasal obstruction' named entity 'olfactory' named entity 'genetic variability' named entity 'Charlson comorbidity index' named entity 'loss of smell' named entity 'anosmia'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software